Department of Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN, USA.
Curr Cardiol Rep. 2014 May;16(5):478. doi: 10.1007/s11886-014-0478-3.
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. Patients may present with a wide variety of symptoms, ranging from relatively asymptomatic to heart failure, recurrent syncope, angina, or sudden death. Once diagnosed, a thorough clinical, anatomic and physiologic assessment should be undertaken. Treatment options include both pharmacologic and invasive therapies, with a goal to reduce symptoms and possibly extend longevity. Traditionally, the "gold standard" for treating severe obstructive HCM has been ventricular septal myotomy-myomectomy. Since its introduction in 1994, alcohol septal ablation (ASA) has emerged as an acceptable alternative in patients who meet strict anatomic criteria, and has been supported in recent guidelines. We review the indications, technique, competency requirements, alternatives, outcomes, complications, and future directions of ASA.
肥厚型心肌病（HCM）是最常见的遗传性心脏病。患者可能表现出各种症状，从相对无症状到心力衰竭、反复晕厥、心绞痛或猝死不等。一旦确诊，应进行全面的临床、解剖和生理评估。治疗选择包括药物治疗和侵入性治疗，目标是减轻症状并可能延长寿命。传统上，治疗严重梗阻性 HCM 的“金标准”一直是室间隔心肌切开术-心肌切除术。自 1994 年引入以来，酒精室间隔消融术（ASA）已成为符合严格解剖标准的患者的一种可接受的替代方法，并在最近的指南中得到支持。我们回顾了 ASA 的适应证、技术、能力要求、替代方法、结果、并发症和未来方向。
